TRANSCODE THERAPEUTICS INC (RNAZ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.06-4.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RNAZ
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
RNAZ — capital allocation — Material
Dated 2026-08-03
Material Modification to Rights of Securityholders. To the extent required by
Why it matters: Enrollment rates show if the trial can succeed. They also show if the company can attract participants.
Supportive ifEnrollment meets the target number of patients on time.
Worry ifEnrollment is much slower than planned. This raises concerns about the trial's success.
Why it matters: Financing is key for clinical trials and operations. Good news could help stability.
Supportive ifTransCode gets more money or partners to help with clinical development.
Worry ifTransCode has trouble getting needed funding, which affects trial progress.
Why it matters: Updates will show how TransCode is doing financially. This affects funding for clinical trials.
Supportive ifThere will be news about new funding or partnerships for TTX-MC138.
Worry ifNot getting more funding or bad news on current financing is a concern.
Why it matters: Fixing compliance issues is key for TransCode's stock listing and investor trust.
Worry ifTransCode fixed Nasdaq issues. It still meets the listing rules.
Less concerning ifMore Nasdaq notices about compliance problems are worrying.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$441 on $10,000 · ±4.4% | How much price usually moves either way. |
| Bad day | $888 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,680 loss on $10,000 · 86.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Successful financing is important. It helps fund clinical trials and other needs.
Supportive ifTransCode completes the sale of up to $14 million in common stock. This is under the Standby Equity Purchase Agreement.
Worry ifTransCode does not get the needed financing. This affects its ability to continue trials.
Why it matters: Starting the Phase 2a trial is a key step for TTX-MC138's development. It shows progress in treating metastatic cancers.
Supportive ifAnnouncement of the Phase 2a trial starting in colorectal cancer patients by the end of Q3 2026.
Worry ifDelay or cancellation of the Phase 2a trial announcement.
Why it matters: The Annual Meeting can affect how shareholders feel and how the company is run.
Worry ifThe Annual Meeting went well. Shareholders approved all proposals.
Less concerning ifFurther adjournments or failure to pass key proposals.
Why it matters: Financing updates show how much money the company has. They also show if it can pay for trials.
Supportive ifThe financing deal is confirmed, and the funds are secured.
Worry ifThe financing deal was not finalized or there are delays in funding.
Why it matters: Updates on patient outcomes can show the effectiveness of TTX-MC138. This is crucial for future trials.
Watch forMore patients are showing stable disease or better results in the Phase 1a trial.
Also watch forNo new patients have stable disease or have had bad outcomes.